乐
乐观
乐观 · 25%APUS
$2.05
情景价格
$2.685
-0.044 (-1.65%)收盘时
Loading chart…
- 最高
- 2.752
- 开盘
- 2.670
- 成交量加权均价
- 2.66
- 成交量
- 15.08K
- 市值
- —
- 最低
- 2.530
- 成交额
- 40.05K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
AI 分析 of Apimeds Pharmaceuticals US Inc (APUS)
卖出Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
估值指标
Apimeds Pharmaceuticals US Inc（APUS）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。
Alphio AI 对 APUS 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
8.510-13NewsfilterMindWave Lists NILA Token on Pionex Exchange
- 7.510-09Newsfilter
MindWave Signs Three Blockchain Agreements Across Diverse Industries
8.507-28GlobenewswireMindChain: The World's First Fully Insured Blockchain Launching Soon
- 8.507-28Newsfilter
MindWave Launches World's First Fully Insured Blockchain
8.505-06NASDAQ.COMApimeds Reaches Settlement with Inscobee, Clearing Path for Merger
APUS 常见问题 —— 由 Alphio AI 解答
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions. It operates in the Healthcare sector.
Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。